Stable sugar levels key to better outcomes

The findings shed new light on the importance of visit-to-visit variability for predicting future mortality and quality of life in diabetic patients.

Using patients from the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial of intensive glucose control and blood pressure lowering in type 2 diabetics, visit-to-visit variability (VVV) of HbA1c and glucose was evaluated from five measurements taken at visits three, six, 12 and 24 months after